Spots Global Cancer Trial Database for myelogenous
Every month we try and update this database with for myelogenous cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Epigenetic Reprogramming in Relapse/Refractory AML | NCT03263936 | Acute Myelogeno... | Decitabine Vorinostat Filgrastim (G-C... Fludarabine Cytarabine | 1 Year - 25 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| AC220 for Children With Relapsed/Refractory ALL or AML | NCT01411267 | Lymphoblastic L... Myelogenous Leu... | AC220 Cytarabine Etoposide Methotrexate | 1 Month - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| TKI Discontinuation in CML Patients of China | NCT03251352 | Leukemia Myelogenous Chronic BCR-ABL (Breakp... Positive | 18 Years - | Shenzhen Second People's Hospital | ||
| A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | NCT02130557 | Leukemia, Myelo... | Bosutinib Imatinib | 18 Years - | Pfizer | |
| A Study Of Panobinostat In Children With Refractory Hematologic Malignancies | NCT01321346 | Lymphoblastic L... Myelogenous Leu... Hodgkin's Disea... Non-Hodgkin's L... | Panobinostat Cytarabine Panobinostat | 8 Years - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy | NCT02638467 | Leukemia Myelogenous Chronic BCR-ABL Positiv... | Bosutinib Bone Marrow Tra... Bone Marrow cel... | 18 Years - 70 Years | University of Milano Bicocca | |
| Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR) | NCT00760877 | CHRONIC MYELOGE... | Nilotinib Imatinib | 18 Years - | Novartis | |
| Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy | NCT02638467 | Leukemia Myelogenous Chronic BCR-ABL Positiv... | Bosutinib Bone Marrow Tra... Bone Marrow cel... | 18 Years - 70 Years | University of Milano Bicocca | |
| Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors | NCT02228382 | Previously Trea... | Bosutinib | 18 Years - | Pfizer | |
| Epigenetic Reprogramming in Relapse/Refractory AML | NCT03263936 | Acute Myelogeno... | Decitabine Vorinostat Filgrastim (G-C... Fludarabine Cytarabine | 1 Year - 25 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation | NCT06427811 | Philadelphia Ch... | Asciminib | 18 Years - | Novartis | |
| AC220 for Children With Relapsed/Refractory ALL or AML | NCT01411267 | Lymphoblastic L... Myelogenous Leu... | AC220 Cytarabine Etoposide Methotrexate | 1 Month - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | NCT02130557 | Leukemia, Myelo... | Bosutinib Imatinib | 18 Years - | Pfizer | |
| AC220 for Children With Relapsed/Refractory ALL or AML | NCT01411267 | Lymphoblastic L... Myelogenous Leu... | AC220 Cytarabine Etoposide Methotrexate | 1 Month - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML | NCT01861002 | Lymphoblastic L... Myelogenous Leu... | Azacytidine Fludarabine Cytarabine Intrathecal (IT... Intrathecal Met... | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
